Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 8, 2007, Pages 1286-1292

  Lee, Yi Chia ^a   Lin, Jaw Town ^a   Wang, Hsiu Po ^a   Chiu, Han Mo ^a   Wu, Ming Shiang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cytochrome P450 2C19; Gastroesophageal reflux disease; Genetic polymorphism; Proton pump inhibitor test

Indexed keywords

CYTOCHROME P450 2C19; DNA; RABEPRAZOLE;

ADULT; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOSCOPY; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKOCYTE; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTIVE VALIDITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE;

EID: 34547672651     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04942.x     Document Type: Article

References (32)

1. Lee YC, Wang HP, Chiu HM et al. Comparative analysis between psychological and endoscopic profiles in patients with gastroesophageal reflux disease: a prospective study based on screening endoscopy. J. Gastroenterol. Hepatol. 2006 21 : 798 804.
2. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann. Intern. Med. 2004 140 : 518 27.
3. Wang WH, Huang JQ, Zheng GF et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis. Arch. Intern. Med. 2005 165 : 1222 8.
4. Juul-Hansen P, Rydning A, Jacobsen CD, Hansen T. High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand. J. Gastroenterol. 2001 36 : 806 10.
5. Fock KM, Talley N, Hunt R et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J. Gastroenterol. Hepatol. 2004 19 : 357 67.
6. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002 51 : 885 92.
7. Lee YC, Wang HP, Chiu HM et al. GABRA6 genetic polymorphism is associated with the risk of functional heartburn in Chinese. J. Gastroenterol. Hepatol. 2007 22 : 227 33.
8. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin. Pharmacol. Toxicol. 2004 95 : 2 8.
9. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003 23 : 460 71.
10. Goldstein JA, Ishizaki T, Chiba K et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 7 : 59 64.
11. Lee YC, Wang HP, Chiu HM et al. Patients with functional heartburn are more likely to report retrosternal discomfort during wireless pH monitoring. Gastrointest. Endosc. 2005 62 : 834 41.
12. Rosaida MS, Goh KL. Gastro-oesophageal reflux disease, reflux oesophagitis and non-erosive reflux disease in a multiracial Asian population: a prospective, endoscopy based study. Eur. J. Gastroenterol. Hepatol. 2004 16 : 495 501.
13. Ohning GV, Walsh JH, Pisegna JR, Murthy A, Barth J, Kovacs TO. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment. Pharmacol. Ther. 2003 17 : 1109 14.
14. Miner P. Review article: relief of symptoms in gastric acid-related diseases - correlation with acid suppression in rabeprazole treatment. Aliment. Pharmacol. Ther. 2004 20 (Suppl. 6 20 9.
15. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. 1999 13 (Suppl. 3 27 36.
16. Horai Y, Kimura M, Furuie H et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment. Pharmacol. Ther. 2001 15 : 793 803.
17. Dent J, Brun J, Fendrick AM et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999 44 (Suppl. 2 S1 S16.
18. Dickman R, Emmons S, Cui H et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment. Pharmacol. Ther. 2005 22 : 547 55.
19. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 1994 269 : 15419 22.
20. Wong WM. Use of proton pump inhibitor as a diagnostic test in NCCP. J. Gastroenterol. Hepatol. 2005 20 (Suppl. S14 17.
21. Fass R, Ofman JJ, Gralnek IM et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch. Intern. Med. 1999 159 : 2161 8.
22. Carlsson R, Dent J, Watts R et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur. J. Gastroenterol. Hepatol. 1998 10 : 119 24.
23. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand. J. Gastroenterol. 1998 33 : 15 20.
24. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand. J. Gastroenterol. 1997 32 : 965 73.
25. Wong WM, Lim P, Wong BC. Clinical practice pattern of gastroenterologists, primary care physicians, and otolaryngologists for the management of GERD in the Asia-Pacific region: the FAST survey. J. Gastroenterol. Hepatol. 2004 19 (Suppl. 3 S54 60.
26. Habu Y, Maeda K, Kusuda T et al. 'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. J. Gastroenterol. 2005 40 : 1029 35.
27. Chang SS, Lu CL, Chao JY et al. Unchanging trend of adenocarcinoma of the esophagus and gastric cardia in Taiwan: a 15-year experience in a single center. Dig. Dis. Sci. 2002 47 : 735 40.
28. Wong WM, Lam SK, Hui WM et al. Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese - prevalence and spectrum of the disease. Aliment. Pharmacol. Ther. 2002 16 : 2037 42.
29. Wu JC, Chan FK, Ching JY, Leung WK, Lee YT, Sung JJ. Empirical treatment based on 'typical' reflux symptoms is inappropriate in a population with a high prevalence of Helicobacter pylori infection. Gastrointest. Endosc. 2002 55 : 461 5.
30. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet. 2005 20 : 153 67.
31. Xia HH, Lai KC, Lam SK et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment. Pharmacol. Ther. 2003 17 : 369 77.
32. Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999 45 : 172 80.